Skip to main content
Dryad

Data from: Dual-mode microfluidic immunostaining device for diagnostic biomarkers detection and tumor microenvironment evaluation

Data files

Jan 09, 2026 version files 83.59 MB

Click names to download individual files

Abstract

The limited availability of tissue samples from rare tumors poses a major barrier to advances in precise diagnosis, prognostic evaluation, and therapeutic research—challenges exemplified by primary central nervous system diffuse large B‑cell lymphoma (PCNS‑DLBCL). Here, we developed a dual-mode microfluidic immunostaining (Dumi) device, which integrates diagnostic and research workflows into a single, automated platform, reducing tissue section consumption by over 90 %. Using just 1–2 slides, it enables both regional detection of biomarkers for subtyping diagnostic (≤ 16) and construction of multiplex tumor microenvironment (TME) maps. Joint analysis of multi-region diagnostic biomarkers in the TME map indicates that tumor cell subpopulations defined by specific diagnostic biomarkers can actively shape their in situ microenvironmental niche. Dumi offers an efficient, cost-effective, and multifunctional immunostaining method, overcoming the limitations of scarce tissue resources and providing a clinically accessible solution to the diagnostic and therapeutic challenges of rare tumors.